<DOC>
	<DOCNO>NCT00063869</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy etanercept comparison placebo double-blind , parallel , randomized fashion subject idiopathic pulmonary fibrosis ( IPF ) fail previous therapy . The treatment period 1 year . The primary objective evaluation safety efficacy . Secondary : The secondary objective evaluate quality life ( QoL ) pharmacokinetics ( PK ) .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Etanercept Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis IPF base American Thoracic Society ( ATS ) guideline Subjects endstage Previous treatment etanercept TNF antagonist ( eg , TNF monoclonal antibody soluble TNFreceptor ) Receipt investigational drug biological agent within 4 week screen visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Fibrosis , Pulmonary</keyword>
	<keyword>Pulmonary Fibroses</keyword>
	<keyword>Fibroses , Pulmonary</keyword>
</DOC>